Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AtriCure (ATRC) Capital Expenditures (2016 - 2025)

AtriCure (ATRC) has disclosed Capital Expenditures for 16 consecutive years, with -$6.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures fell 160.2% to -$6.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.3 million, a 88.99% decrease, with the full-year FY2025 number at $1.3 million, down 88.99% from a year prior.
  • Capital Expenditures was -$6.2 million for Q4 2025 at AtriCure, down from $6.6 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $15.0 million in Q4 2022 to a low of -$7.8 million in Q4 2023.
  • A 5-year average of $1.6 million and a median of $747500.0 in 2024 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: plummeted 2714.76% in 2021, then surged 1971.38% in 2022.
  • AtriCure's Capital Expenditures stood at -$5.5 million in 2021, then skyrocketed by 372.52% to $15.0 million in 2022, then tumbled by 152.02% to -$7.8 million in 2023, then soared by 231.98% to $10.3 million in 2024, then crashed by 160.2% to -$6.2 million in 2025.
  • Per Business Quant, the three most recent readings for ATRC's Capital Expenditures are -$6.2 million (Q4 2025), $6.6 million (Q3 2025), and -$261000.0 (Q2 2025).